Matinas Biopharma Holdings, Inc. (MTNB) Q4 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the Martinez Biopharma 2022 fourth quarter and full year conference call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jody Kane. Thank you, Jody. You may begin. This is Jody King with LHA. Thank you for participating in today's call. Speaking on today's call from Matinus Biopharma will be Jerry Jabbour, Chief Executive Officer, and Keith Kaczynski, Chief Financial Officer. We also have Dr. Terry Matrovich, Chief Development Officer, and Dr. Terry Ferguson, Chief Medical Officer, available to answer questions during our Q&A session. I'd like to remind listeners that remarks made during this call may state management's future intentions, hopes, beliefs, expectations, or projections. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements are made pursuant to the safe harbor provisions of the federal securities law. These forward-looking statements are based on the team's biofarmers' current expectations and actual results could differ materially. As a result, you should not place undue reliance on forward-looking statements. Some of the factors that could cause actual results to differ materially from those contemplated by such forward-looking statements are discussed in the periodic reports, MATINAS Biopharma files with the Securities and Exchange Commission. These documents are available in the investor section of the company's website and on the SEC's website. Furthermore, the content of this conference...